AbbVie (ABBV) Financial Analysis & Valuation | Quarter Chart
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor f... more
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The compa... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $521.50B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | Robert A. Michael |
| IPO Date | 2013-01-02 | CAGR | 9.55% |
| Employees | 57,000 | Website | www.abbvie.com |
| Div. Yield | 2.58% | Payout Ratio | 116% |
| Buy Back Yield | 0.32% | Total Yield | 2.9% |
ABBV chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $463.92B | P/E | 28.95 | Forward P/E | 18.22 | PEG | 0.02 |
| P/S | 7.17 | P/B | -80 | P/CF | 24.36 | P/FCF | 26 |
| Sales | $66.01B | Sales 1Y | 10.68% | Sales 3Y | 19.73% | Sales 5Y | 19.66% |
| EPS | $10.19 | EPS 1Y | 337.95% | EPS 3Y | 59.29% | EPS 5Y | 38.77% |
| Sales QoQ | 2.44% | EPS QoQ | 16.67% | Sales QoQ Avg | 2.83% | EPS QoQ Avg | 326.29% |
| Gross Margin | 76.25% | Operating Margin | 35.53% | Profit Margin | 15.68% | ROCE | 25.09% |
| ROA | 8% | ROE | -224% | Altman Z Score | 2.91 | Piotroski Score | 7 |
| Current Ratio | 0.81 | Quick Ratio | 0.69 | Cash Ratio | 0.16 | Op. CF Ratio | 0.08 |
| Debt/Equity | -11.93 | Debt/Assets | 0.52 | Lt Debt/Equity | -10.53 | Lt Debt/Cap. | 1.1 |
| Intrst Cov. | 8.15 | Inventory Turnover | 3.06 | Asset Turnover | 0.49 | Receivables Turnover | 4.78 |
| Enterprise Value | $463.92B | P/E Ratio | 28.95 |
| Forward P/E | 18.22 | PEG Ratio | 0.02 |
| P/S Ratio | 7.17 | P/B Ratio | -80 |
| P/CF Ratio | 24.36 | P/FCF Ratio | 26 |
| EPS | $10.19 | EPS Growth 1Y | 337.95% |
| EPS Growth 3Y | 59.29% | EPS Growth 5Y | 38.77% |
| Revenue Growth 1Y | 10.68% | Gross Margin | 76.25% |
| Operating Margin | 35.53% | Profit Margin | 15.68% |
| ROE | -224% | ROA | 8% |
| ROCE | 25.09% | Current Ratio | 0.81 |
| Quick Ratio | 0.69 | Cash Ratio | 0.16 |
| Debt/Equity | -11.93 | Interest Coverage | 8.15 |
| Altman Z Score | 2.91 | Piotroski Score | 7 |
AbbVie (ABBV) valuation & financials
AbbVie (ABBV) has a market capitalization of $521.50B and trades at a price-to-earnings ratio of 28.9. It operates in the Healthcare sector (Drug Manufacturers - General).
AbbVie's revenue grew +10.7% over the last year.
AbbVie's next earnings report is scheduled for February 3, 2027 before market open (provider scheduled date); analysts estimate EPS of $3.89. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW) · Novartis (NVS)